Brian Park, PharmD

All articles by Brian Park, PharmD

Lasmiditan, a First-In-Class Migraine Treatment, Now Available

February 3, 2020

This first-in-class, serotonin (5-HT) 1F receptor agonist is believed to exert its therapeutic effects both centrally and peripherally.

Neurobehavioral Disorders

Potential Presence of Foreign Substance Prompts Recall of Alprazolam Lot

Brian Park, PharmD

October 28, 2019

Mylan Pharmaceuticals announced the voluntary recall of one lot of alprazolam 0.5mg tablets to the consumer/user level due to the potential presence of a foreign substance.

Next post in Neurobehavioral Disorders

Brian Park, PharmD

All articles by Brian Park, PharmD

Lasmiditan, a First-In-Class Migraine Treatment, Now Available

Potential Presence of Foreign Substance Prompts Recall of Alprazolam Lot

Bipolar Disorder Associated With Increased Risk for Parkinson Disease